• Highly sensitive BEAMing digital PCR technology
  • Detection of 36 EGFR sensitizing and resistance mutations
  • A more rapid and minimally invasive assessment of EGFR mutations, as compared to tissue biopsy
  • Catalog Number ZR150220

Detection of cell-free tumor DNA in metastatic Non-Small-Cell-Lung-Cancer (NSCLC) patients with a simple blood draw – The OncoBEAM™ EGFR Kit V2 (RUO)*

The OncoBEAM™ EGFR Kit V2 (RUO) is a Research Use Only (RUO) reagent kit for the qualitative detection of mutations in the human EGFR oncogene exons 18, 19, 20 and 21 using DNA extracted from 2 mL plasma.

*for research use only, not for diagnostic use



EGFR Mutation Frequency in Non-Small Cell Lung Cancer

EGFR Mutation Frequency in Non-Small Cell Lung Cancer

  • Testing for the most common EGFR mutations (exon 19 deletions and the L858R mutation in exon 21) is recommended to select patients likely to benefit from first and second generation EGFR tyrosine kinase inhibiton (TKI) therapy. 2,3
  • Clinical guidelines also recommend assessment of EGFR T790M at disease progression, 2,3 which accounts for up to 60% of acquired resistance to first and second generation EGFR TKI target therapies. 4 Osimertinib therapy is recommended for patients with EGFR T790M resistance mutation who have progressed on EGFR TKI therapy. 2,3
  • Clinical outcomes of patients with T790M positive plasma results have been shown to be equivalent to those of patients with T790M positive tissue-based tumor results, suggesting that plasma genotyping may be considered instead of tissue biopsy to detect the EGFR T790M mutation. 5 However, if the plasma biopsy is negative, then a tissue biopsy is recommended if feasible. 5
  • EGFR C797S mutation is associated with resistance to osimertinib in EGFR T790M positive patients. 6
  • The prevalent EGFR mutations in exons 19, 20 and 21 from the basis of the OncoBEAM EGFR Kit (RUO).
OncoBEAM™ Advantages

OncoBEAM™ Advantages

Safety and Convenience

Minimally invasive, few risks

Accurate Information

Blood sample evaluation represents current mutational status of patient's disease; Information of tumor dynamics in real time

No Selection Bias

Evaluate primary tumor and metastases with one sample

Ability to Monitor

Allows multiple measurements to assess drug response and resistance

Time Sensitive

Rapid turnaround time from biopsy to result 1





  1. Sacher AG et al. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol 2016; 2(8): 1014-1022.
  2. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer 6.2017
  3. Novello S et al. Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2016; 27(suppl 5):v1-v27.
  4. Yu HA et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19(8):2240-2247.
  5. Oxnard GR et al. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2016; 34(28):3375-3382.
  6. Thress KS et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M. Nat Med 2015; 21(6):560-562.

Sales Support


Create Pdf